variants by studying the RNase Z activity in an in vitro system. We also modeled the residues affected by a missense mutation in solved RNase Z structures, providing insight into enzyme structure and function. Finally, we show that primary fibroblasts from the affected individuals have elevated levels of unprocessed mitochondrial RNA precursors. Our study thus broadly confirms the correlation of ELAC2 variants with severe infantile-onset forms of HCM and mitochondrial respiratory chain dysfunction.
One rare missense variant associated with the occurrence of prostate cancer processing enzymes, the mitoribosomal proteins, mitochondrial aminoacyl tRNA synthetases, and others are encoded by the nuclear genes (Hallberg & Larsson, 2014; Rorbach & Minczuk, 2012) . More than 50 nuclear-encoded mitochondrial proteins involved in mitochondrial gene expression are linked to heritable disorders (Frazier, Thorburn, & Compton, 2017; Rahman & Rahman, 2018; Stenton & Prokisch, 2018; Van Haute et al., 2015) .
Human mt-mRNAs, mt-tRNAs, and mt-rRNAs are transcribed as part of large polycistronic precursor transcripts encoded by the 16.6 kb mtDNA. The mitochondrial gene sequences for mt-rRNA and, in the majority of cases, mt-mRNA are separated by mt-tRNA sequences, leading to the proposed "tRNA punctuation" model of RNA processing (Anderson et al., 1981; Ojala, Montoya, & Attardi, 1981) . Processing of the intervening mt-tRNAs generates individual mt-mRNAs and mt-rRNAs. In human mitochondria, endonucleolytic cleavage at the 5′ and 3′ termini of mt-tRNAs is performed by the RNase P complex (Holzmann et al., 2008) and the RNase Z activity of ELAC2, respectively (Brzezniak, Bijata, Szczesny, & Stepien, 2011; Rossmanith, 2011) . Two human nuclear genes encode orthologues of the bacterial RNase Z (elaC): ELAC1 (MIM# 608079, RefSeq: NM_0018696.2, NP_061166.1) and ELAC2 (MIM# 605367, RefSeq: NM_018127.6, NP_060597.4). The ELAC1 gene encodes a short form of RNase Z (also referred to as RNase Z S ) that is located in the cytosol, but its function in humans is unknown (Rossmanith, 2011) .
ELAC2 codes for a long form of RNase Z (also referred to as RNase Z L ). Alternative translation initiation of ELAC2 mRNA has been proposed to produce two ELAC2 protein isoforms; one targeted to the mitochondria, the other to the nucleus. Translation of the longer isoform initiates at the methionine codon 1 (M1) and the first 31 amino acids of this isoform are predicted to contain a mitochondrial targeting sequence (MTS; Rossmanith, 2011) . This longer isoform of ELAC2 has a well-characterized role in mitochondrial pre-tRNA processing (Brzezniak et al., 2011; Dubrovsky, Dubrovskaya, Levinger, Schiffer, & Marchfelder, 2004; Lopez Sanchez et al., 2011; Rossmanith, 2011) . If the translation is initiated at the methionine codon 16 (M16; relative to the longer mitochondrially-targeted form)
ELAC2 is targeted to the nucleus. Recent data on the activity of ELAC2 in vivo, generated using a knockout mouse model, revealed that it has a nonredundant role in the processing of mtDNA-encoded tRNAs and that it contributes to the processing of nuclear-encoded tRNA, miRNA, and C/D box snoRNAs (Siira et al., 2018 ).
Thus far, seven different pathogenic mutations have been reported in ELAC2-associated mitochondrial dysfunction. In our previous work, we investigated the functional consequences of ELAC2 variants in patients presenting with a recessively inherited form of hypertrophic cardiomyopathy (HCM), hypotonia, lactic acidosis, and failure to thrive (Haack et al., 2013) . This previous work identified a total of four disease alleles (coding for p.Phe154-Leu, p.Arg211*, p.Leu423Phe, and p.Thr520Ile) in three families. One of these, the variant coding for p.Phe154Leu, was also recently reported as prevalent in consanguineous Arabian families affected by infantile cardiomyopathy (Shinwari et al., 2017) . In contrast, a homozygous splice site mutation (c.1423 + 2 T>A) in ELAC2 has been associated with developmental delay and minimal cardiac involvement in a consanguineous Pakistani family (Akawi et al., 2016) . A single heterozygous ELAC2 variant coding for p.Pro32Arg was recently reported in an infant presenting with encephalopathy, epilepsy, and growth and developmental retardation (Kim, Kim, Lee, & Cheon, 2017) . The patient also developed Tetralogy of Fallot, however, without evidence of cardiomyopathy. Since the transmission pattern of ELAC2-related disease in the families reported previously (Akawi et al., 2016; Haack et al., 2013; Shinwari et al., 2017) was consistent with recessive inheritance, the relevance of this variant remains unclear. Finally, an Assyrian patient presenting with chorea, psychosis, acanthocytosis, and displaying a prolonged survival has been identified to carry compound heterozygous ELAC2
variants coding for p.Gly132Arg and p.Ser347Phe. The patient had mild cardiac hypertrophy without evidence of pump failure. Muscle biopsy did not indicate any evidence of respiratory chain defect, despite the presence of cytochrome oxidase (COX)-negative and ragged-red fibers (Paucar et al., 2018) .
In the present work, we report the identification of 16 additional ELAC2 variants (ten missense, two frameshift, and four splice mutations) in individuals who present with mitochondrial respiratory chain deficiency, HCM, and lactic acidosis. We provide further evidence for the pathogenicity of the two previously reported and new evidence for eight newly identified missense variants by studying the RNase Z activity in an in vitro system. Fibroblasts from the individuals with novel ELAC2 variants showed elevated levels of unprocessed mt-tRNA precursors. The combination of in vitro ELAC2
activity and mtRNA processing analysis provided the pathogenicity evidence for all patients harboring the previously unreported ELAC2
variants. Moreover, modeling of the missense substitutions provided additional insight into the effects of substitutions on enzyme structure.
| MATERIALS AND METHODS

| Ethics statement
Informed consent for diagnostic and research-based studies was obtained for all subjects in accordance with the Declaration of Helsinki protocols and approved by local institutional review boards.
| Exome sequencing, variant prioritization, reevaluation, and verification
For reevaluation of the ELAC2 variants in P1 (previously reported as patient 27 in Taylor et al., 2014) and also for the analysis of the ELAC2 splice variants in P6 and P8, RNA purification from fibroblasts and cDNA retrotranscription was used to verify the identified variants, we used RNeasy mini kit (QIAGEN) and GoTaq 2-Step RTqPCR System (Promega), respectively, according to the manufacturers' protocols. Primers used for cDNA amplification are available upon request.
For P2 and P10-P13 exome sequencing and variant prioritization was performed by commercial laboratories: P2 -Fulgent Diagnostics, P10, and P12 -Baylor College of Medicine, Human Genome Sequencing Center, P11-Centogene, as described in previously (Trujillano et al., 2017) and P13 -UCL.
For P3, targeted NGS sequencing using a custom Ampliseq panel targeting 55 mitochondrial translation genes (IAD62266) and subsequent Ion Torrent PGM sequencing was performed essentially as described previously . Candidate gene sequencing was performed for all coding exons of the ELAC2 gene (including intron-exon boundaries) using M13-tagged amplicons and BigDye v3.1 sequencing kit (Life Technologies). Capillary electrophoresis was performed using an ABI3130xl (Life Technologies). NGS variant confirmation was performed by Sanger sequencing using oligonucleotides targeting the exons of interest.
For P4 and P8, genomic DNA from the individuals and their parents was isolated from whole blood using the chemagic DNA Blood Kit special (PerkinElmer,Waltham, MA), according to the manufacturer's protocol. Exome sequencing was performed as previously described (Kremer et al., 2017) . Exonic regions were enriched using the SureSelect Human All Exon kit (50Mb_v5) from Agilent followed by sequencing as 100 bp paired-end runs on an Illumina HiSeq. 2500. Reads were aligned to the human reference genome (UCSC Genome Browser build hg19) using ). Identification of single-nucleotide variants and small insertions and deletions (indels) was performed with SAMtools (version 0.1.19). For analysis of rare bi-allelic variants, only variants with a minor allele frequency (MAF) of less than 1% in our internal
Munich database of 14,000 exomes were considered.
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For P5, WES was undertaken using previously described methodologies and bioinformatics variant filtering pipelines (Bonnen et al., 2013) For P6 and P9 a targeted custom panel (Nextera rapid capture; Illumina) containing genes responsible for mitochondrial disorders was used (Ardissone et al., 2018) . Variant filtering was performed as described in Legati et al. (2016 
| RNA isolation and RNA Northern blot
RNA extraction and Northern blot were performed essentially as described previously (Pearce, Rorbach et al., 2017) . Briefly, RNA was extracted from cells at 60-80% confluency using TRIzol reagent (Ambion), following the manufacturerʼs instructions. Gels run on the Bio-Rad Mini-Sub Cell GT were used for the separation of RNA samples (5 μg per sample) for northern blot. A half volume of Gel Loading Buffer II (Ambion) was added to samples before heating at 55°C for 10 min, chilled on ice for 2 min, and then loaded onto a 1.2%
Agarose gel (1× MOPS; 0.7 M formaldehyde). Electrophoresis was carried out at 4°C in 1× MOPS, 0.3 M formaldehyde and 10 μg/ml ethidium bromide. Gels were semi-dry blotted onto a positively charged nylon membrane (Hybond-N+; GE Healthcare) for >12 hr, after which the membrane was cross-linked and hybridized with [ 32 P] labeled antisense RNA probes as described previously .
| Recombinant protein purification and mutagenesis
Wild type and mutant ELAC2 proteins (GenBank Accession number: NM_018127.6) were expressed from Gly50 to Gln826 using the baculovirus system and insect SF9 cells, and affinity purified as previously described (Yan, Zareen, & Levinger, 2006 (Levinger & Serjanov, 2012) . Mutant enzymes were used at a higher concentration than wild type depending on the impairment factor ( Figure S1 ). (Thiers & Vallee, 1957) , with our previous studies indicating higher ELAC2
processing activity on mt-tRNA precursors on the presence of Ca 2+ (Yan et al., 2006) . Reactions were sampled after 5, 10, and 15 min incubation at 37°C, electrophoresed on denaturing 6%
polyacrylamide gels and images were obtained from dried gels 
| In silico modeling
The recently published structure of Saccharomyces cerevisiae RNase Z (PDB 5MTZ; Ma et al., 2017 ) was used to model the position and function of residues at which substitutions were observed in this study. Molecular structures were displayed using PyMOL. The overall structure is shown using cartoon and individual residues with sticks, polar contacts with dashed lines and hydrophobic residues with dots. The active site and regions proximal to it, which directly contact the substrate, are found in the carboxy domain of ELAC2 (a long form RNase Z, RNase Z L ), and were superimposed onto the corresponding regions in the only available co-crystal structure of RNase Z with pre-tRNA substrate, from Bacillus subtilis (PDB 4GCW; Pellegrini, Li de la Sierra-Gallay, Piton, Gilet, & Condon, 2012).
3 | RESULTS
| Summary of clinical features of the investigated patient cohort
We investigated 13 families with a cohort of 13 infants, most presenting with early-onset, syndromic cardiomyopathy, with HCM being present in 10 subjects, dilated cardiomyopathy (DCM) in two subjects, and one subject being reported without any cardiac problems. All subjects with the exception of P10 also presented with lactic acidosis. These clinical features raised suspicion of mitochondrial disease. Indeed, a biochemical defect of the mitochondrial respiratory chain (MRC) complexes was detected in all investigated subjects (n = 10), with isolated Complex I deficiency prevailing in most of the patients (7/10) and the remaining subjects presenting with combined MRC deficiencies. The onset of symptoms was either from birth (P1, P2, and P11), neonatal (P5), infantile (P4, P6-P10, P12 and P13) or early childhood (P3). Most of the patients also displayed developmental delay. Evidence of brain involvement was found in P2 and P9. P7 and P10 were successfully treated by heart transplantation at age 3.8 years and 10 months, respectively (Parikh et al., 2016; Santorelli et al., 2002) , whereas P12 underwent two failed cardiac transplants. The summary of genetic, biochemical, and clinical findings of all individuals is provided in Table 1 . Pedigrees of investigated families and detailed case reports are provided in the Supporting Information Material.
| Identification of ELAC2 variants
Using whole exome sequencing (WES) or targeted, panel-based nextgeneration sequencing, we screened a group of patients presenting with MRC deficiencies and cardiomyopathy (Table 1 ). Three of the analyzed patients (P5, P11, and P13) harbored the previously described homozygous c.460 T>C (p.Phe154Leu) ELAC2 variant (Haack et al., 2013; Shinwari et al., 2017) . All remaining patients of the analyzed cohort harbored novel missense (n = 10), frameshift (n = 2) or splice site (n = 4) mutations ( Figure 1 and Table 1 ). P2 harbored a novel consensus splice variant (c.1423 + 1 G>A) in the same splice site as previously reported patients of Pakistani origin (c.1423 + 2 T>A; Akawi et al., 2016) . All these variants were extremely rare or not reported in public databases and predicted damaging using Polyphen-2 (Adzhubei et al., 2010) .
Of note, P1 was previously included in WES analysis based on multiple MRC complex deficiency together with a cohort of 53 patients (patient 27) . This previous study 
| In vitro RNase Z activity of mutant ELAC2 enzymes
Despite the increased utility of genetic testing, providing proof of pathogenicity of novel variants remains challenging and follow up functional studies in vitro should therefore be included as an integral part of the evaluation. To provide evidence for the pathogenicity of identified ELAC2 variants, we set out to study the RNase Z activity of the enzyme in the presence of the missense substitutions or the truncating variants resulting from frameshift mutations. Substitutions were introduced into the human ELAC2 cDNA (Genbank Acc# NM_018127.6) and the mutant proteins were expressed in baculovirus using insect SF9 cells (Saoura, Pinnock, Pujantell-Graell, & Levinger, 2017) . Affinity-purified recombinant mutant proteins were tested using precursor mt-tRNA LeuUUR or mt-tRNA Ile as substrates.
To assess the utility of the in vitro system to evaluate the pathogenicity of the novel ELAC2 variants, we first tested the three previously reported missense mutations (p.Phe154Leu, p.Leu423Phe, p.Thr520Ile), that have been extensively characterized in terms of pathogenicity in our previous paper (Haack et al., 2013) . (Haack et al., 2013 Next, we expressed and tested 10 novel missense variants detected in our patients using pre-mt-tRNA Leu(UUR) as a substrate ( Figure   2c ; Table 4 ).
Two novel frameshift variants were detected in our patient cohort: p.Ile153Tyrfs*6 and p.Cys670Serfs*14, both resulting in premature stop codons (Table 1 ). The p.Ile153Tyrfs*6 mutation results in early truncation of the ELAC2 protein, eliminating all functional motifs, and was therefore considered a priori as loss of function; expression and assay of this mutant were not attempted.
On the other hand, p.Cys670Serfs*14 occurs closer to the carboxy terminus. We, therefore, tested p.Cys670Ser*14 for enzymatic activity. This mutant expressed poorly, however, and displayed no detectable enzyme activity, confirming the functional importance of domains beyond the truncation, including motif V and other functional elements ( Figure S3 ). Taken T A B L E 2 Kinetic parameters of three previously reported pathogenic missense mutations in the ELAC2 endonuclease with the pre-mt- 
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Assessing the clinical significance of sequence variants that may alter splicing, especially in the context of tissue-specific disease manifestation, can be challenging (Spurdle et al., 2008) . In four patients from our cohort, P2, P3, P6, and P8, compound heterozygous splice-site mutations were present. The analysis of the processing of mtRNA of these four patients revealed accumulation of unprocessed mitochondrial tRNA-rRNA or tRNA-mRNA junctions, providing evidence for the disruptive nature of the detected splice variants. Taken together, the observed defect in the processing of mt-tRNA junctions in the patient-derived cell lines provides additional evidence for the pathogenicity of all detected, novel missense, frameshift, and splice site ELAC2 variants.
| In silico characterization of mutations in ELAC2
Having established the damaging nature of the detected ELAC2 missense mutations both in vitro and in living cells, we set out to develop a rationale for the observed biochemical impairment, as summarized in Table S1 . To this end, we modeled all 13 substitutions (3 published previously and 10 novel) into the structure of S. cerevisiae RNase Z (Trz1; PDB 5MTZ; Ma et al., 2017) . Analysis of the ELAC2 structure indicates that the amino and carboxy domains arose from a duplication, with the active site being retained in the carboxy domain and the flexible arm being preserved in the amino domain (Schilling et al., 2005) . The amino and carboxy domains are tethered by a flexible linker ( Figure S3 ). Substitutions at Arg68, Phe154, Gln388 are found in the amino domain, Leu422 and Leu423 are in the linker domain (flexible tether), whereas Pro493, Thr520, Arg564, Lys660, Arg680, Tyr729, His749, and Arg781 are located in the carboxy domain of ELAC2 (Figure 4 ; Figure S3 ).
Using the Trz1 structure, we have modeled the residues Arg68, Phe154, and Gln388 in the amino domain in which substitutions were found associated with HCM. Modeling using the Trz1 structure is less obviously effective in cases where the residues in the S. cerevisiae
Trz1 sequence are not conserved ( Figure S3 ); in these cases, however, the overall sequence similarity in the region suggests structural relationships of inferred secondary structure elements. All T A B L E 3 Kinetic parameters of the novel missense mutations in the ELAC2 endonuclease with the pre-mt-tRNA Leu(UUR) substrate three residues are located close to the domain interface. The modeling of Arg68 and Gln388 suggests the substitutions at these sites could disrupt the structure and folding of ELAC2 through their indirect effects on a number of polar contacts across the amino-and carboxy domain interface ( Figure S4 ). Phe154 is conserved and aligns with Trz1 Phe103 (Figure S3 ). Across the N-and C-domain interface Phe154 closely approaches the motif II region, suggesting that reducing the size of the hydrophobic side chain in the case of p.Phe154Leu could affect the packing of a region which is critical for metal ion binding and catalysis ( Figure S5 ).
Contiguous residues Leu422 and Leu423 are located in the linker domain of the human ELAC2 at the apex of the loop between two twisted beta sheets in the amino domain. Substitutions at these positions may affect the structure due to subtle changes in regional hydrophobicity ( Figure S6 ).
We next set out to model residues in the carboxy domain (Pro493, Thr520, Arg564, Lys660, Ala680, Tyr729, His749, and Arg781). All of these but two could be effectively modeled using Arg564 is not conserved and is located in the long, overall poorly conserved region between motifs II and III, with no significant polar or hydrophobic contacts in this region of the Trz1 structure ( Figure S3 ). The mutated residue is reasonably close to motif II, implying that subtle regional changes may impair catalysis when transmitted to this motif.
The side chain of conserved Lys660 (Lys693 in the Trz1 structure) found in β24 is predicted to make polar contacts with the backbone of the preceding residues within 12 residues of the F I G U R E 4 ELAC2 substitutions mapped on the structure of Saccharomyces cerevisiae RNase Z. The structure of S. cerevisiae RNase Z (Trz1, PDB#5MTZ; Ma et al., 2017 ) is shown in cartoon using PyMol. The amino domain, inter-domain linker, and carboxy domain are colored green, blue, and pale green, respectively. Three views are shown to effectively visualize all the substitutions. All 13 ELAC2 substitutions (3 published previously (Haack et al., 2013) , and 10 novel) are shown in all three views. Residues are labeled with S. cerevisiae RNase Z numbers and the numbers in brackets are for the H. sapiens ELAC2 residues. Some residues are not conserved between S. cerevisiae and H. sapiens RNase Z. Residues Arg68, Phe154, Gln388 localized in the amino domain are marked in red; Leu422 and Leu423 are in linker (also marked in red); Pro493, Thr520, Arg564, Lys660, Arg680, Tyr729, His749, Arg781 are in the carboxy domain and indicated in purple. (a) View with amino domain up, carboxy domain down and linker behind with the H. sapiens residues Phe154, Leu422, Leu423, Lys660, Ala680, Tyr729 and Arg781 labeled. (b) The ELAC2 model is rotated with linker on left with the residues Arg68, Gln388 and Arg564 labeled. (c) ELAC2 rotated with linker on right and the residues Pro493, Thr520 and His749 labeled. Note: the residues at Arg68, Phe154, and Gln388 in H. sapiens ELAC2 map to the domain interface motif IV aspartate (Figures S4 and S8) . Loss of these side chainspecific polar contacts with the p.Lys660Ala substitution could, therefore, affect the position of Asp666, the motif IV aspartate, which is critical for metal ion binding and catalysis ( Figure S8B ).
Similarly, Ala680; Ser715 in the Trz1 structure) located below the base of β25 could, when replaced by the bulkier valine in the case of the Ala680Val mutation, indirectly affects the location of the Motif IV aspartate ( Figure S8B ). Finally, His749 (Ser787 in the Trz1 structure), is predicted to be contiguous with the aspartate in the AxD loop and substitution at this position could perturb that residue.
The AxD loop is conserved and the aspartate in this loop makes polar contacts with the backbone of a conserved leucine at the start and a conserved asparagine at the end of the PxKxRN loop ( Figure S8B ; cf, Wang et al., 2012) .
The Arg781 residue is present on a long C-terminal α-helix.
Although this residue is not conserved, the region where it is found is generally highly polar. In metazoan ELAC2 enzymes this region consists of frequently interspersed acidic and basic residues while in Saccharomyces cerevisiae it is principally acidic ( Figure S3 ). In S.
cerevisiae RNase Z, the long α-helix is curved and approaches the predicted location where the substrate acceptor stem is clamped by polar contacts between Lys495 of the PxKxRN loop and nt + 1-2 of the pre-tRNA substrate and between Arg728 of the motif V loop and nt 71-72-73 of the substrate ( Figure 5 ; Figure S9 ). The region where Arg781 is found could thus modulate both substrate binding and catalysis, consistent with impairment of the p.Arg781His mutant which arises from the combination of a reduction in k cat and increased K M , (Table 3 and Table 4 ).
| DISCUSSION
The mitochondrial genome encodes key subunits of the OXPHOS system and RNA components needed for mitochondrial translation, with nuclear genes encoding the proteins responsible for mtDNA transcription, posttranscriptional RNA processing, and translation. Recent years have seen rapid development in our understanding of these machineries both in human health and in disease state RebeloGuiomar, Powell, Van Haute, & Minczuk, 2019) . Dysfunction of mitochondrial gene expression, caused by mutations in either the mitochondrial or nuclear genomes, is associated with a diverse group of human disorders characterized by impaired mitochondrial respiration. Within this group, an increasing number of mutations have been identified in nuclear genes involved in endonucleolytic processing of precursor mtRNA (Deutschmann et al., 2014; Haack et al., 2013; Metodiev et al., 2016) and in mtRNA epitranscriptome shaping (Bykhovskaya, Casas, Mengesha, Inbal, & Fischel-Ghodsian, 2004; Chakraborty et al., 2014; Garone et al., 2017; Ghezzi et al., 2012; Kopajtich et al., 2014; Nicholls, Rorbach, & Minczuk, 2013; Powell, Kopajtich et al., 2015; Van Haute et al., 2016; Wedatilake et al., 2016; Yarham et al., 2014; Zeharia et al., 2009 ).
| Genotype-phenotype correlation
Clinical syndromes associated with defects in mtRNA metabolism are characterized by the variable combination of encephalopathy, myopathy, sideroblastic anemia, cardiomyopathy, hearing loss, optic atrophy, and renal or liver dysfunction (Boczonadi, Ricci, & Horvath, 2018; D'Souza & Minczuk, 2018) . HCM and lactic acidosis are frequent presentations in some mitochondrial diseases related to dysfunctional mt-tRNA maturation, such as those caused by biallelic variants in MTO1 (MIM# 614667), GTPBP3 (MIM# 608536), AARS2
(MIM# 612035) and RARS2 (MIM# 611524; Ghezzi et al., 2012; Gotz et al., 2011; Kopajtich et al., 2014; Lax et al., 2015) . With multiple novel variants in ELAC2, our study further underscores HCM as a manifestation of dysfunctional mitochondrial gene expression. (Akawi et al., 2016) . Both of these variants affect the same consensus donor sequence (exon 15), and it would be interesting to further explore the features of pre-mRNA splice site selection of this particular donor site in cardiac tissue. Interestingly, mtDNA depletion was detected in the hypertrophic heart and not the skeletal muscle of P7 (Santorelli et al., 2002) . To the best of our knowledge, quantitative abnormalities of the mtDNA have so far never been associated with defects in mtRNA processing, and additional observations are necessary to confirm this association.
| Enzymatic mechanism of ELAC2
The results of our in vitro analysis of the ELAC2 mutants could be used to design further experiments aimed at better understanding the enzymology of this mitochondrial RNase Z. In particular, the p.Pro493Leu and p.Tyr729Cys substitutions most severely impaired enzyme function, resulting in~1% of WT enzyme activity.
No mutations were found which interfere directly with metal ion binding or catalysis, although numerous such substitutions, constructed by site-directed mutagenesis, greatly impair catalysis, between 500-10,000-fold relative to WT (Karkashon, Hopkinson, & Levinger, 2007; Zareen, Yan, Hopkinson, & Levinger, 2005) . Catalytic efficiencies with WT enzyme are generally lower using mitochondrial substrates than with nuclear-encoded substrates and the lower catalytic efficiency is more pronounced with mt-tRNA Ile than with mt-tRNA Leu(UUR) . Two levels of catalytic activity were thus observed, between nuclear versus mitochondrial and further among different mitochondrial tRNAs (Levinger & Serjanov, 2012; Yan et al., 2006 ). To explain the first level distinction, mitochondrial tRNAs generally have a weaker and noncanonical secondary and tertiary structure (reviewed in Florentz, Sohm, Tryoen-Toth, Putz, & Sissler, 2003) . For example, mt-tRNA Leu(UUR) displays a heterogeneous secondary structure and among mitochondrial tRNAs, it is closer to canonical than mt-tRNA Ile , which displays AU rich stems including an A/C mismatch in the T-stem (Levinger, Morl, & Florentz, 2004) . Wild type substrate structures that reduce wild type ELAC2 catalytic efficiencies may thus lead to more pronounced impairment with missense substitutions which otherwise were not observed with more canonical nuclear-encoded substrates. 
| Conclusions
